Pilot efficacy trial of abt‐200 in patients with major depressive disorder

Depression

Volumn 2, Issue 6, 1994, Pages 315-318

  Sramek, John J ^a   Jasinsky, Olga ^b   Chang, Stephen ^b   Shu, Vincent ^b   Kashkin, Ken ^b   Kennedy, Sara ^a   Sadd, Carrie ^a   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

ABT 200; clinical trial; depression

Indexed keywords

3 PHENYL 1 [(1,2,3,4 TETRAHYDRO 5,6 METHYLENEDIOXY 1 NAPHTHYL)METHYL]PYRROLIDINE; 3 PHENYL 1 [(1,2,3,4 TETRAHYDRO 5,6 METHYLENEDIOXY 1 NAPHTHYL)METHYL]PYRROLIDINE METHANESULFONATE; ANTIDEPRESSANT AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG TOLERANCE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0028818062     PISSN: 10626417     EISSN: 15227162     Source Type: Journal    
DOI: 10.1002/depr.3050020607     Document Type: Article

References (16)

1. Practice guideline for major depressive disorder in adults
2. Symptomatic volunteers in multicenter drug trials
3. Acceleration of beta‐receptor desensitization in combined administration of antidepres‐sants and phenoxybenzamine
4. Montgomery‐Åsberg Depression Scale: Reliability and validity
5. 2‐adrenoceptor antagonist treatment
6. The assessment of anxiety states by rating
7. A rating scale for depression
8. Preclinical pharmacological actions of (±)‐(1′R*, 3R*‐3‐phenyl‐l‐[1′,2′,3′,4′‐tetrahydro‐5′,6′‐methylene‐dioxy‐1′‐naphthalenyl)methyl]pyrrolidine methanesulfonate (ABT‐200), a potential antidepressant agent that antagonizes alpha‐2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine
9. 2, and β‐adrenoreceptor sensitivity
10. The timing, specificity and clinical prediction of tricyclic drug effects in depression
11. Methodology of measuring the efficacy of anti‐depressants
12. Duration of antidepressant drug treatment: What is an adequate trial?
13. Use of pattern analysis to identify true drug response
14. Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant alpha‐2 antagonist treatment
15. Synthesis and pharmacological characterization of ABT‐200: A putative novel anti‐depressant combining potent α‐2 antagonism with moderate NE uptake inhibition